| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | 1.96B | 14.87 | 378.37 | 33.97% | 29.28% | 21.28% | 2.25% | 0.21 |
| ARGXargenx SE | 50.33B | 813.24 | 63.63 | 78.6% | 23.34% | 15.14% | 0.01 | |
| INVAInnoviva, Inc. | 1.48B | 19.76 | 54.89 | 15.54% | 32.78% | 12.61% | 12.75% | 0.65 |
| GLPGGalapagos N.V. | 2.24B | 34.03 | 30.38 | 14.99% | -151.94% | -15.16% | 0.00 | |
| PTGXProtagonist Therapeutics, Inc. | 5.3B | 84.75 | 20.04 | 6.24% | 21.94% | 7.11% | 3.45% | 0.02 |
| ALMSAlumis Inc. Common Stock | 2.84B | 24.17 | -2.33 | -11.08% | -63.71% | 0.12 | ||
| PHATPhathom Pharmaceuticals, Inc. | 1.17B | 14.98 | -2.83 | 80.01% | -186.53% | |||
| ORKAOruka Therapeutics, Inc. | 1.57B | 32.50 | -6.51 | -22.44% | 0.00 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 20.06M | 30.93M | 231K | 28.63M | 27.36M | 26.58M | 60M | 434.43M |
| Revenue Growth % | - | - | - | 0.54% | -0.99% | 122.93% | -0.04% | -0.03% | 1.26% | 6.24% |
| Cost of Goods Sold | 247K | 317K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -247K | -317K | 20.06M | 30.93M | 231K | 28.63M | 27.36M | 26.58M | 60M | 434.43M |
| Gross Margin % | - | - | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Gross Profit Growth % | - | -0.28% | 64.29% | 0.54% | -0.99% | 122.93% | -0.04% | -0.03% | 1.26% | 6.24% |
| Operating Expenses | 14.79M | 32.67M | 57.96M | 73.19M | 80.75M | 93.14M | 153.2M | 157.95M | 153.65M | 181.59M |
| OpEx % of Revenue | - | - | 2.89% | 2.37% | 349.58% | 3.25% | 5.6% | 5.94% | 2.56% | 0.42% |
| Selling, General & Admin | 2.96M | 6.96M | 11.78M | 13.7M | 15.75M | 18.64M | 27.2M | 31.74M | 33.49M | 43.46M |
| SG&A % of Revenue | - | - | 0.59% | 0.44% | 68.18% | 0.65% | 0.99% | 1.19% | 0.56% | 0.1% |
| Research & Development | 11.83M | 25.7M | 46.18M | 59.5M | 65M | 75.98M | 126.01M | 126.22M | 120.16M | 138.13M |
| R&D % of Revenue | - | - | 2.3% | 1.92% | 281.4% | 2.65% | 4.61% | 4.75% | 2% | 0.32% |
| Other Operating Expenses | 0 | -34K | 0 | 0 | -1K | -1.48M | 0 | 0 | 0 | 0 |
| Operating Income | -14.79M | -32.67M | -37.9M | -42.27M | -80.52M | -64.52M | -125.84M | -131.37M | -93.65M | 252.84M |
| Operating Margin % | - | - | -1.89% | -1.37% | -348.58% | -2.25% | -4.6% | -4.94% | -1.56% | 0.58% |
| Operating Income Growth % | -0.59% | -1.21% | -0.16% | -0.12% | -0.9% | 0.2% | -0.95% | -0.04% | 0.29% | 3.7% |
| EBITDA | -14.55M | -32.35M | -37.49M | -41.74M | -79.82M | -63.57M | -123.07M | -128M | -90.34M | 253.67M |
| EBITDA Margin % | - | - | -1.87% | -1.35% | -345.53% | -2.22% | -4.5% | -4.82% | -1.51% | 0.58% |
| EBITDA Growth % | -0.61% | -1.22% | -0.16% | -0.11% | -0.91% | 0.2% | -0.94% | -0.04% | 0.29% | 3.81% |
| D&A (Non-Cash Add-back) | 247K | 317K | 406K | 527K | 703K | 948K | 2.77M | 3.37M | 3.31M | 826K |
| EBIT | -14.79M | -32.67M | -36.96M | -39.72M | -77.71M | -64.52M | -125.84M | -131.37M | -93.65M | 252.84M |
| Net Interest Income | 0 | 0 | 948K | 2.57M | 2.64M | 302K | 443K | 4.06M | 14.9M | 26.32M |
| Interest Income | 19K | 242K | 948K | 2.57M | 2.81M | 900K | 443K | 4.06M | 14.9M | 26.32M |
| Interest Expense | 0 | 0 | 0 | 0 | 169K | 598K | 0 | 0 | 0 | 0 |
| Other Income/Expense | -64K | -4.51M | 940K | 2.55M | 2.64M | -329K | 294K | 3.98M | 14.7M | 26.57M |
| Pretax Income | -14.86M | -37.18M | -36.96M | -39.72M | -77.88M | -64.84M | -125.55M | -127.39M | -78.95M | 279.41M |
| Pretax Margin % | - | - | -1.84% | -1.28% | -337.13% | -2.27% | -4.59% | -4.79% | -1.32% | 0.64% |
| Income Tax | 64K | 0 | 0 | -799K | -691K | 1.3M | 0 | 0 | 0 | 4.22M |
| Effective Tax Rate % | 1% | 1% | 1% | 0.98% | 0.99% | 1.02% | 1% | 1% | 1% | 0.98% |
| Net Income | -14.86M | -37.18M | -36.96M | -38.92M | -77.19M | -66.15M | -125.55M | -127.39M | -78.95M | 275.19M |
| Net Margin % | - | - | -1.84% | -1.26% | -334.14% | -2.31% | -4.59% | -4.79% | -1.32% | 0.63% |
| Net Income Growth % | -0.34% | -1.5% | 0.01% | -0.05% | -0.98% | 0.14% | -0.9% | -0.01% | 0.38% | 4.49% |
| Net Income (Continuing) | -14.86M | -37.18M | -36.96M | -38.92M | -77.19M | -66.15M | -125.55M | -127.39M | -78.95M | 275.19M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.52 | -5.72 | -2.09 | -1.74 | -2.98 | -1.92 | -2.65 | -2.52 | -1.39 | 4.23 |
| EPS Growth % | -0.34% | -1.27% | 0.63% | 0.17% | -0.71% | 0.36% | -0.38% | 0.05% | 0.45% | 4.04% |
| EPS (Basic) | -2.52 | -5.72 | -2.09 | -1.74 | -2.98 | -1.92 | -2.65 | -2.52 | -1.39 | 4.47 |
| Diluted Shares Outstanding | 5.88M | 6.5M | 17.69M | 22.36M | 25.89M | 34.4M | 46.32M | 49.04M | 56.76M | 65.08M |
| Basic Shares Outstanding | 5.88M | 6.5M | 17.69M | 22.36M | 25.89M | 34.4M | 46.32M | 49.04M | 56.76M | 61.57M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 14.21M | 83.24M | 150.95M | 137.5M | 145.31M | 315.61M | 340.74M | 243.08M | 355.58M | 591.64M |
| Cash & Short-Term Investments | 11.92M | 77.6M | 144M | 128.85M | 133.02M | 305.81M | 326.9M | 237.35M | 341.62M | 418.91M |
| Cash Only | 4.05M | 21.08M | 106.03M | 82.23M | 33.01M | 117.36M | 123.67M | 125.74M | 186.73M | 97.25M |
| Short-Term Investments | 7.87M | 56.52M | 37.97M | 46.62M | 100.01M | 188.45M | 203.24M | 111.61M | 154.89M | 321.66M |
| Accounts Receivable | 715K | 2.24M | 1.82M | 4.59M | 6.75M | 3.82M | 5.33M | 52K | 10.33M | 168.49M |
| Days Sales Outstanding | - | - | 33.04 | 54.14 | 10.67K | 48.72 | 71.15 | 0.71 | 62.85 | 141.56 |
| Inventory | 0 | -7.65M | -8.75M | 2.14M | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 315K | 8.16M | 10.24M | -205K | 754K | 10K | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 639K | 10.75M | 12.79M | 1.97M | 9.61M | 8.86M | 6.96M | 4.85M | 2.37M | 153.08M |
| Property, Plant & Equipment | 609K | 562K | 879K | 861K | 7.72M | 6.41M | 6.73M | 4.63M | 2.15M | 12.61M |
| Fixed Asset Turnover | - | - | 22.82x | 35.92x | 0.03x | 4.46x | 4.06x | 5.75x | 27.92x | 34.46x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 30K | 10.15M | 11.46M | 450K | 0 | 2M | 0 | 0 | 0 | 140.25M |
| Other Non-Current Assets | 0 | 34K | 450K | 450K | 450K | 450K | 225K | 225K | 225K | 225K |
| Total Assets | 14.85M | 93.99M | 163.73M | 139.47M | 154.92M | 324.47M | 347.69M | 247.93M | 357.95M | 744.73M |
| Asset Turnover | - | - | 0.12x | 0.22x | 0.00x | 0.09x | 0.08x | 0.11x | 0.17x | 0.58x |
| Asset Growth % | 0.44% | 5.33% | 0.74% | -0.15% | 0.11% | 1.09% | 0.07% | -0.29% | 0.44% | 1.08% |
| Total Current Liabilities | 3.13M | 6.43M | 42.55M | 26.16M | 35.41M | 40.24M | 44.02M | 31.18M | 21.27M | 47.4M |
| Accounts Payable | 1.25M | 1.16M | 1.26M | 5.71M | 2.79M | 3.08M | 1.6M | 3.64M | 772K | 1.61M |
| Days Payables Outstanding | 1.84K | 1.34K | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 69K | 0 | 1000K |
| Other Current Liabilities | 149K | 120K | 6.83M | 9.5M | 4.64M | 6.41M | 7.13M | 4.97M | 6.79M | 23.69M |
| Current Ratio | 4.54x | 12.94x | 3.55x | 5.26x | 4.10x | 7.84x | 7.74x | 7.80x | 16.71x | 12.48x |
| Quick Ratio | 4.54x | 14.13x | 3.75x | 5.17x | 4.10x | 7.84x | 7.74x | 7.80x | 16.71x | 12.48x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 2.12M | 0 | 547K | 799K | 39.55M | 4.62M | 3.66M | 1.14M | 0 | 22.03M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 9.79M | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 5.96M | 4.5M | 3.66M | 1.14M | 0 | 10.36M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 221K | 0 |
| Other Non-Current Liabilities | 2.12M | 0 | 547K | 799K | 0 | 121K | 0 | 0 | -221K | 11.68M |
| Total Liabilities | 5.25M | 6.43M | 43.1M | 26.96M | 74.95M | 44.86M | 47.67M | 32.32M | 21.27M | 69.43M |
| Total Debt | 0 | 0 | 0 | 0 | 17.01M | 5.96M | 5.86M | 3.66M | 1.14M | 10.87M |
| Net Debt | -4.05M | -21.08M | -106.03M | -82.23M | -15.99M | -111.4M | -117.81M | -122.09M | -185.59M | -86.38M |
| Debt / Equity | - | - | - | - | 0.21x | 0.02x | 0.02x | 0.02x | 0.00x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.04x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.34x |
| Interest Coverage | - | - | - | - | -476.46x | -107.89x | - | - | - | - |
| Total Equity | 9.6M | -64.59M | -101.55M | -140.47M | 79.96M | 279.61M | 300.02M | 215.61M | 336.68M | 675.29M |
| Equity Growth % | 0.21% | -7.73% | -0.57% | -0.38% | 1.57% | 2.5% | 0.07% | -0.28% | 0.56% | 1.01% |
| Book Value per Share | 1.63 | -9.93 | -5.74 | -6.28 | 3.09 | 8.13 | 6.48 | 4.40 | 5.93 | 10.38 |
| Total Shareholders' Equity | 9.6M | -64.59M | -101.55M | -140.47M | 79.96M | 279.61M | 300.02M | 215.61M | 336.68M | 675.29M |
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1K | 1K |
| Retained Earnings | -27.42M | -64.59M | -101.55M | -140.47M | -217.66M | -283.81M | -409.36M | -536.75M | -615.71M | -340.52M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -102K | -245K | -6K | -233K | -221K | 28K | -299K | -359K | -105K | -82K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -14.38M | -29.97M | 3.87M | -49.95M | -41.53M | -72.48M | -107.86M | -108.14M | -70.24M | 184.15M |
| Operating CF Margin % | - | - | 0.19% | -1.62% | -179.77% | -2.53% | -3.94% | -4.07% | -1.17% | 0.42% |
| Operating CF Growth % | -0.86% | -1.08% | 1.13% | -13.9% | 0.17% | -0.75% | -0.49% | -0% | 0.35% | 3.62% |
| Net Income | -14.86M | -37.18M | -36.96M | -38.92M | -77.19M | -66.15M | -125.55M | -127.39M | -78.95M | 275.19M |
| Depreciation & Amortization | 247K | 317K | 406K | 527K | 2.5M | 2.56M | 2.77M | 3.37M | 3.31M | 2.9M |
| Stock-Based Compensation | 99K | 2.13M | 4.24M | 6.92M | 8.35M | 7.9M | 16.39M | 24.2M | 29.29M | 37.55M |
| Deferred Taxes | -8K | 151K | 0 | -658K | -775K | 1.44M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 83K | 4.72M | 625K | 206K | -557K | 781K | 1.83M | -549K | -4.38M | -8.88M |
| Working Capital Changes | 52K | -112K | 35.56M | -18.02M | 26.14M | -19.02M | -3.31M | -7.77M | -19.51M | -122.61M |
| Change in Receivables | -192K | -1.59M | -1.82M | -2.77M | -757K | 3.34M | -915K | 4.24M | 0 | -155M |
| Change in Inventory | 0 | 0 | 5.53M | 3.85M | 757K | -3.34M | 915K | -4.24M | 0 | 0 |
| Change in Payables | 898K | -115K | 91K | 4.43M | -3M | 309K | -1.39M | 2.04M | -2.93M | 842K |
| Cash from Investing | -8.26M | -59.33M | 15.82M | 2.21M | -53.71M | -90.97M | -15.86M | 91.47M | -39.26M | -299.48M |
| Capital Expenditures | -399K | -379K | -666K | -486K | -967K | -471K | -1.1M | -795K | -609K | -1.35M |
| CapEx % of Revenue | - | - | 0.03% | 0.02% | 4.19% | 0.02% | 0.04% | 0.03% | 0.01% | 0% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -7.87M | 32K | 16.49M | 2.7M | -52.74M | -90.49M | -14.76M | 91.47M | 0 | 0 |
| Cash from Financing | 17.42M | 106.31M | 65.55M | 24.11M | 46.04M | 247.63M | 129.92M | 18.84M | 170.48M | 25.85M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 57K | 151K | 1.01M | 934K | 1.78M | 2.79M | 6.09M | 4.29M | 38.38M | -600K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -14.78M | -30.35M | 3.21M | -50.43M | -42.49M | -72.95M | -108.97M | -108.93M | -70.84M | 182.8M |
| FCF Margin % | - | - | 0.16% | -1.63% | -183.96% | -2.55% | -3.98% | -4.1% | -1.18% | 0.42% |
| FCF Growth % | -0.84% | -1.05% | 1.11% | -16.73% | 0.16% | -0.72% | -0.49% | 0% | 0.35% | 3.58% |
| FCF per Share | -2.51 | -4.67 | 0.18 | -2.26 | -1.64 | -2.12 | -2.35 | -2.22 | -1.25 | 2.81 |
| FCF Conversion (FCF/Net Income) | 0.97x | 0.81x | -0.10x | 1.28x | 0.54x | 1.10x | 0.86x | 0.85x | 0.89x | 0.67x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -169.31% | - | - | - | -96.53% | -36.79% | -43.32% | -49.41% | -28.59% | 54.39% |
| Return on Invested Capital (ROIC) | -531.9% | - | - | - | -94.41% | -41.68% | -53.87% | -71.47% | -57.43% | 51.25% |
| Gross Margin | - | - | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| Net Margin | - | - | -184.2% | -125.87% | -33414.29% | -231.07% | -458.94% | -479.26% | -131.59% | 63.34% |
| Debt / Equity | - | - | - | - | 0.21x | 0.02x | 0.02x | 0.02x | 0.00x | 0.02x |
| Interest Coverage | - | - | - | - | -476.46x | -107.89x | - | - | - | - |
| FCF Conversion | 0.97x | 0.81x | -0.10x | 1.28x | 0.54x | 1.10x | 0.86x | 0.85x | 0.89x | 0.67x |
| Revenue Growth | - | - | - | 54.14% | -99.25% | 12293.07% | -4.44% | -2.84% | 125.73% | 624.05% |
| 2019 | 2020 | 2021 | 2024 | |
|---|---|---|---|---|
| Development Services | - | - | - | 15.3M |
| Development Services Growth | - | - | - | - |
| License and Collaboration Agreement | - | - | 18.6M | - |
| License and Collaboration Agreement Growth | - | - | - | - |
| License And Collaborative Revenue | 200K | 28.6M | - | - |
| License And Collaborative Revenue Growth | - | 14200.00% | - | - |
| Financial Service Other | - | 1.5M | - | - |
| Financial Service Other Growth | - | - | - | - |
Protagonist Therapeutics, Inc. (PTGX) has a price-to-earnings (P/E) ratio of 20.0x. This is roughly in line with market averages.
Protagonist Therapeutics, Inc. (PTGX) reported $209.2M in revenue for fiscal year 2024.
Protagonist Therapeutics, Inc. (PTGX) grew revenue by 624.1% over the past year. This is strong growth.
Yes, Protagonist Therapeutics, Inc. (PTGX) is profitable, generating $45.9M in net income for fiscal year 2024 (63.3% net margin).
Protagonist Therapeutics, Inc. (PTGX) has a return on equity (ROE) of 54.4%. This is excellent, indicating efficient use of shareholder capital.
Protagonist Therapeutics, Inc. (PTGX) generated $63.7M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.